Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 2Leukemia, B-Cell 2Leukemia 2Hematologic Diseases 2Bronchiolitis Obliterans Syndrome 2Paraproteinemias 1Neoplasms, Plasma Cell 1Neoplasms 1Monoclonal Gammopathy of Undetermined Significance 1Lymphoma, B-Cell 1Lymphoma 1Immunoproliferative Disorders 1Immune System Diseases 1Blood Protein Disorders 1

Interventions

Cyclophosphamide 8Rituximab 7fludarabine 6dacetuzumab 6fludarabine phosphate 5blinatumomab 4Bortezomib 4ibrutinib 3Melphalan 3Lenalidomide 3Ifosfamide 3Etoposide 3Dexamethasone 3Bendamustine Hydrochloride 3AP 1903 reagent 3ponatinib 2cobomarsen 2Whole-Body Irradiation 2Vorinostat 2Vincristine 2Tacrolimus 2Prednisone 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mycophenolic Acid 2Mesna 2Doxorubicin 2Carboplatin 2Busulfan 2Brentuximab Vedotin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Immunoproliferative Disorders × KW-2478 × Lymphoid × Clear all
NCT01063907 2024-04-25

A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma

Kyowa Kirin Co., Ltd.

Phase 1/2 Completed
95 enrolled 13 charts
LymphoidOther hematologic neoplasmPlasma cell

Bronchiolitis Obliterans Syndrome, Blood Protein Disorders, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Paraproteinemias, Leukemia, B-Cell, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡